Is Eli Lilly a Better Stock to Buy and Hold Over the Next 10 Years Than Novo Nordisk?
It's rare for a prescription drug to become part of the cultural landscape. However, that's exactly what has happened with Ozempic. Hollywood celebrities and social media have put the GLP-1 agonist in the spotlight.
Novo Nordisk (NYSE: NVO) has no complaints. Thanks largely to the tremendous success of Ozempic and its sibling Wegovy, shares of the Danish biopharmaceutical company have soared.
However, another drugmaker hopes to push Ozempic and Wegovy to the side. And its share price has skyrocketed, too. Is Eli Lilly (NYSE: LLY) a better stock to buy and hold over the next 10 years than Novo Nordisk?
Source Fool.com